Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Status:
Completed
Trial end date:
2017-04-03
Target enrollment:
Participant gender:
Summary
Establishment of safety profile of HuMax-CD38 when given as monotherapy in participants with
multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies
and without further established treatment options.